Literature DB >> 7699031

Suggested modifications for disk diffusion susceptibility testing criteria for levofloxacin and sparfloxacin following tests with a predictor panel of ciprofloxacin-resistant clinical isolates.

L D Sutton1, R N Jones.   

Abstract

A predictor panel of 300 clinical bacterial isolates (200 resistant to ciprofloxacin) was used to compare 5-micrograms disk diffusion test results with the MICs of ofloxacin (control), levofloxacin, and sparfloxacin. Regression analysis demonstrated high correlations between the methods for all three fluoroquinolones (r > or = 0.95). In order to minimize disk diffusion testing errors among the fluoroquinolone-resistant strains, the following modifications to previously proposed or published interpretive criteria were suggested: for levofloxacin, susceptible at > or = 17 mm (< or = 2 micrograms/ml) and resistant at < or = 13 mm (> or = 8 micrograms/ml); for sparfloxacin, susceptible at > or = 20 mm (< or = 1 microgram/ml) and resistant at < or = 16 mm (> or = 4 micrograms/ml). The study control drug, ofloxacin, did not appear to possess a significant error rate (5% minor error) when fluoroquinolone-resistant strains were tested, and no modifications were proposed. Under these proposed interpretive criteria, the absolute categorical agreements between standardized susceptibility testing methods for levofloxacin and sparfloxacin results were 91.3 and 94.0%, respectively (< or = 0.3% major errors and nil very major errors).

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7699031      PMCID: PMC227897          DOI: 10.1128/jcm.33.1.146-148.1995

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  14 in total

1.  Use of a predictor panel for development of a new disk for diffusion tests with cefoperazone-sulbactam.

Authors:  P A Bradford; C C Sanders
Journal:  Antimicrob Agents Chemother       Date:  1992-02       Impact factor: 5.191

2.  The penetration of sparfloxacin into human plasma and skin tissues.

Authors:  T Nogita; Y Ishibashi
Journal:  J Antimicrob Chemother       Date:  1991-08       Impact factor: 5.790

3.  In vitro activity of sparfloxacin (AT-4140, CI-978, PD 131501), a new quinolone antimicrobial agent.

Authors:  G M Eliopoulos; K Klimm; M L Grayson
Journal:  Diagn Microbiol Infect Dis       Date:  1990 Jul-Aug       Impact factor: 2.803

4.  Susceptibility tests of anaerobic bacteria: statistical and clinical considerations.

Authors:  C M Metzler; R M DeHaan
Journal:  J Infect Dis       Date:  1974-12       Impact factor: 5.226

5.  In vitro activity of DR-3355, an optically active ofloxacin.

Authors:  T Une; T Fujimoto; K Sato; Y Osada
Journal:  Antimicrob Agents Chemother       Date:  1988-09       Impact factor: 5.191

6.  Tentative interpretive criteria for disk diffusion susceptibility testing of sparfloxacin.

Authors:  P C Fuchs; A L Barry; M A Pfaller
Journal:  J Clin Microbiol       Date:  1993-08       Impact factor: 5.948

7.  Interpretive criteria for disk diffusion susceptibility testing of sparfloxacin.

Authors:  F H Kayser; J Wüst
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-03       Impact factor: 3.267

8.  Comparative in vitro activities of sparfloxacin (CI-978; AT-4140) and other antimicrobial agents against staphylococci, enterococci, and respiratory tract pathogens.

Authors:  A E Simor; S A Fuller; D E Low
Journal:  Antimicrob Agents Chemother       Date:  1990-11       Impact factor: 5.191

9.  In vitro and in vivo antibacterial activities of AT-4140, a new broad-spectrum quinolone.

Authors:  S Nakamura; A Minami; K Nakata; N Kurobe; K Kouno; Y Sakaguchi; S Kashimoto; H Yoshida; T Kojima; T Ohue
Journal:  Antimicrob Agents Chemother       Date:  1989-08       Impact factor: 5.191

10.  Ofloxacin susceptibility testing quality control parameters for microdilution and disk diffusion, and confirmation of disk diffusion interpretive criteria.

Authors:  P C Fuchs; R N Jones; A L Barry; T L Gavan
Journal:  J Clin Microbiol       Date:  1989-01       Impact factor: 5.948

View more
  2 in total

1.  Prevalence of resistance to three fluoroquinolones: assessment of levofloxacin disk test error rates and surrogate predictors of levofloxacin susceptibility. AST Surveillance Group.

Authors:  P C Fuchs; A L Barry; S D Brown
Journal:  Antimicrob Agents Chemother       Date:  1996-07       Impact factor: 5.191

2.  Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489.

Authors:  Peter J Petersen; C Hal Jones; Aranapakam M Venkatesan; Tarek S Mansour; Steven J Projan; Patricia A Bradford
Journal:  Antimicrob Agents Chemother       Date:  2008-11-10       Impact factor: 5.191

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.